ADMA Biologics

Valuation Analysis

About the Company

ADMA Biologics en bref

ADMA Biologics (ADMA) is currently trading at 7,33 € with a market capitalization of 1,7 Md €. The trailing P/E ratio stands at 12.44x, with a forward P/E of 8.59x. The 52-week range spans from 6,25 € to 17,74 €; the current price is 58.7% below the yearly high. Year-over-year revenue growth stands at +15.9%. The net profit margin stands at 32.43%.

💰 Dividende

ADMA Biologics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

5 analystes évaluent ADMA Biologics (ADMA) au consensus : None. L'objectif de cours moyen est de 14,74 €, soit un potentiel de +100.95% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 10,40 € à 18,21 €.

ADMA Biologics : la thèse d'investissement en détail

ADMA Biologics (ADMA) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 15.9% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 61.27%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 43.3% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.

Le scénario baissier

Short interest sits at 12.68% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

The EV/EBITDA multiple of 203.46x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 8.59x is meaningfully below the trailing 12.44x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 100.95% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (12.68%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy ADMA Biologics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.